The October 2017 issue of Pharmafocus is now live!
pharmafile | September 26, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, EMA, Pharmafocus
The October edition of Pharmafocus is now live! You can read it here.
Allergan has found itself in the firing line after its latest marketing move. Not even a full year from CEO Brent Saunders’ announcement of a ‘social contract’ with patients promising to cap price increases, the company has taken the unprecented step of selling its drug rights to a Native American tribe in order to dodge direct competition. Unsurprisingly, patients and competitors are not happy. Get up to speed with our front page story.
In the UK, an industry worried and uncertain over Brexit welcomed the release of Sir John Bell’s Life Sciences Industrial Strategy. We spoke to ABPI Chief Executive Mike Thompson to get his thoughts on a report he called “the right intervention at the right time”.
Across in the US, researchers at the University of Texas have developed a ‘pen’ device which can identify cancerous tissue in just ten seconds. The implications of the technology on cancer treatment are potentially huge, and we spoke to the team to get the full story on what to expect from the device.
As the next home of the EMA headquarters is set to be revealed this month, forced from its current London location by the Brexit referendum, we look at the 19 competing EU member states with exclusive interviews to discover what is being brought to the negotiating table. Find out everything you need to know in the run-up to the final vote in our special feature.
Related Content
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European …
